Charles Schwab Investment Management Inc. Has $89.77 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Charles Schwab Investment Management Inc. lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 817,968 shares of the medical equipment provider’s stock after selling 1,208 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Lantheus were worth $89,772,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of LNTH. CANADA LIFE ASSURANCE Co grew its position in Lantheus by 30.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider’s stock valued at $3,116,000 after acquiring an additional 11,696 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Lantheus by 68.1% during the 1st quarter. Tidal Investments LLC now owns 27,570 shares of the medical equipment provider’s stock valued at $1,716,000 after purchasing an additional 11,168 shares during the last quarter. Hancock Whitney Corp increased its position in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 14,639 shares in the last quarter. LRI Investments LLC bought a new position in Lantheus in the 1st quarter valued at approximately $211,000. Finally, Swedbank AB acquired a new stake in Lantheus in the first quarter valued at approximately $26,346,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

NASDAQ:LNTH opened at $89.53 on Wednesday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a 50 day simple moving average of $102.80 and a two-hundred day simple moving average of $97.04. The company has a market capitalization of $6.22 billion, a PE ratio of 14.94 and a beta of 0.51.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial restated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.